Exhibit





Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions.





	
														
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT
	1. CONTRACT ID CODE


	PAGE    OF   PAGES
    1        3

	2. AMENDMENT/MODIFICATION NO.
P00005
	3.  EFFECTIVE DATE
See Block 16C
	4.  REQUISITION/PURCHASE REQ. NO.


	5. PROJECT NO. (If applicable)



	6. ISSUED BY
	CODE
	ASPR-BARDA
	7.  ADMINISTERED BY (If other than Item 6)
	CODE
	ASPR-BARDA

	ASPR-BARDA
200 Independence Ave., S.W.
Room 640-G
Washington DC 20201
	ASPR-BARDA
200 Independence Ave., S.W.
Room 638-G
Washington DC 20201

	8.  NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)   
EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
EMERGENT PRODUCT DEVLOPMENT GAITHE
300 PROFESSIONAL DR # 100
GAITHERSBURG MD 208793419
	X










X








	9A. AMENDMENT OF SOLICITATION NO.


9B.  DATED (See Item 11)


10A. MODIFICATION OF CONTRACT/ORDER NO.
HHSO100201600030C
10B. DATED (See Item 13)



	CODE     1365869
	FACILITY CODE
	 
	09/30/2016

	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

	      The  above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers          is extended,        is not extended.
Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:
(a) By completing Items 8 and 15, and returning          copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer
submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEGMENT 
TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT
IN  REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter,
provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

	12. ACCOUNTING AND APPROPRIATION DATA (If required)
See Schedule

	13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,
IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

	CHECK ONE
	A.   THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority)  THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

	 

	 
	B.   THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).     

	 
	C.   THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:



	X
	D.   OTHER (Specify type of modification and authority)
FAR 43.103(a) (3) Mutual Agreement of the Parties

	E. IMPORTANT:  Contractor       is not,    x   is required to sign this document and return    1    copies to the issuing office.

	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)
Tax ID Number: [**]
DUNS Number: [**]
The purpose of this modification is to modify ARTICLES B.3. OPTION PRICES, B.5. ADVANCE UNDERSTANDINGS, F.3 DELIVERIES, G.1 CONTRACTING OFFICER, and G.4. INVOICE SUBMISSION.


Funds Obligated Prior to this Modification: $464,692,203
Funds Obligated with Mod #5: $0
Total Funds Obligated to Date: $464,692,203


Expiration Date: September 29, 2021 (Unchanged)
Period of Performance: 09/30/2016 to 09/29/2021

	Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

	15A.  NAME AND TITLE OF SIGNER (Type or print)
Abigail Jenkins    SVP BU HEAD, Vaccines
	16A.  NAME OF CONTRACTING OFFICER
SABRINA J. MCINTYRE

	15B. CONTRACTOR/OFFEROR


/s/ Abigail Jenkins   
(Signature of person authorized to sign)
	15C.  DATE SIGNED


Apr 10, 2020
	16B.  UNITED STATES OF AMERICA


BY  /s/ Sabrina Mcintyre   
      (Signature of Contracting Officer)
	16C.  DATE SIGNED


4/10/20




           STANDARD FORM 30 (REV. 11/2016)
   Previous Edition Unusable        Prescribed by GSA
FAR (48 CFR) 53.243



The purpose of this modification is to modify ARTICLES B.3 OPTION PRICES, B.5 ADVANCE UNDERSTANDINGS, F.3 DELIVERIES, G.1 CONTRACTING OFFICER, and G.4. INVOICE SUBMISSION.
ARTICLE B.3.  OPTION PRICES are hereby modified as follows:
	
							
	CLIN
	Period of Performance
	Supplies/Services
	Doses
	Price per Dose
	Total Cost
	Additional
Doses****

	CLIN 0004
(Option -
Funded)***
	[**] -
09/29/21
	Additional Surge
Capacity (EUA)
	[**]
	[**]
	[**]
	Dose number TBD




[**].
***CLIN 0004 is funded 
****Additional Doses may be delivered to BARDA as consideration under the provision in Article B.5.I. In the event that EBS delivers doses [**] (see Article B.5.I), Emergent will provide a [**]% dose-replacement equivalent of additional doses to the Government. As set forth in Article B.5.l, BARDA may accept [**] if such doses are delivered along with the appropriate number of additional doses (“Additional Doses”). Additional Doses shall be calculated as [**]% of the number of delivered [**].
ARTICLE B.5.  ADVANCE UNDERSTANDINGS is hereby modified as follows:
I.    Stability
BARDA understands that the stability testing is ongoing to support long-term stability of AV7909. The contractor will continue to perform ICH compliant stability studies on AV7909. While EBS and BARDA believe that a [**] will be achieved, this cannot be confirmed until FDA licensure of the vaccine.
For the agreed upon price, AV7909 will be delivered to the SNS that is [**] from the date of manufacture stamped on the vial label.
		
	•
	BARDA does agree to a [**] to the [**] limitation to allow delivery of approximately [**] doses of AV7909 that were initially manufactured as PPQ material intended for qualification of a Redundant Fill Site at PAR.


		
	•
	For CLIN 0004, BARDA agrees to allow delivery of and may accept doses dated [**] if such doses are delivered along with the appropriate number of additional doses (“Additional Doses”). Additional Doses shall be calculated as [**]% of the number of delivered [**]. EBS shall provide the Additional Doses as consideration for BARDA’s acceptance of [**] with a [**] for storage in the Strategic National Stockpile. The Additional Doses will be included with delivery of the [**] at no additional cost to BARDA or the US Government.


ARTICLE F.3.  DELIVERIES is hereby modified as follows:
Email Addresses: CO - [**]
COR - [**]
ARTICLE G.1.  CONTRACTING OFFICER is hereby modified as follows:
The following Contracting Officer (CO) will represent the Government for the purpose of this contract:
[**]
HHS/OS/ASPR/BARDA
200 C St. SW
O’Neill House Office Building
Washington, DC 20515
[**]
ARTICLE G.4.  INVOICE SUBMISSION is hereby modified as follows:
		
	g.
	Invoices shall be delivered electronically to the Contracting Officer (CO), the Contracting Officer’s Representative (COR), PSC, and e-Room electronically. Unless otherwise specified by the Contracting Officer, all deliverables, invoices, and reports furnished to the Government under the resultant contract shall be addressed as follows:


	
			
	[**]
Contracting Officer
HHS/ASPR/BARDA
200 C Street, S.W.
Washington, DC 20024
Email: [**]
	[**]
Contracting Officer Representative
HHS/ASPR/BARDA
200 C Street, S.W.
Washington, DC 20024
Email: [**]
	Email invoices to:


PSC_Invoices@psc.hhs.gov
e-Room






All other terms and conditions of this contract remain unchanged.
End of Modification #5